Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The ...
with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...
In a report released on November 7, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Applied Therapeutics (APLT – ...
Over the past 100 years, GZUCM has cultivated 180, 000 top-degree doctors who are dedicated to the nation and the cause of traditional Chinese medicine, including leading figures represented by ...
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
and in the first European countries for second-line ESCC and first- and second-line non-small cell lung cancer (NSCLC); ...
Intercept’s US president Vivek Devaraj said the pharma company still believes in the evidence supporting the liver disease ...
In the United States, highly purified CBN products are being sold as ... by the University of Sydney Animal Ethics Committee and were in accordance with the Australian Code of Practice for the Care ...
Human trials are now under way ... Sydney has identified a constituent in the cannabis plant that improves sleep. Their ...
Detailed price information for Legend Biotech Corp ADR (LEGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback